Efficacy of Brentuximab Vedotin in Treating Cutaneous t-cell Lymphoma
Ashish Gautma, PhD, MBA
Cutaneous T-cell lymphoma is a rare form of lymphoma that has a poor prognosis when advanced.
Ashish Gautma, PhD, MBA of Takeda Oncology talks about the lasted results from the ALCANZA study that was presented at the 58th Annual ASH Meeting & Exposition.
ALCANZA enrolled 128 previously treated patients with CD-30–expressing cutaneous T-cell lymphoma. They were randomized to receive brentuximab vedotin (1.8 mg/kg intravenously) once every 3 weeks or physician’s choice [oral methotrexate (5–50 mg once weekly) or oral bexarotene (300 mg/m2 once daily for up to 16 weeks).
At 17.5 months of follow-up, the overall response was significantly higher for brentuximab vedotin than for physician’s choice of therapy: 56% vs 13%, respectively (P < .0001). Median progression-free survival was also significantly higher in the brentuximab-treated group: 16.7 months vs 3.5 months (P < .0001).
Kim YH, Whittaker S, Horwitz SM, et al. Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study. Presented at 58th Annual ASH Meeting & Exposition; San Diego, CA;